TB guideline
Dx: pulmonary +extrapulmonary ->>>>>
Recommended regimen
WHO recommends fixed-dose combination (FDC) treatment for both intensive and
continuation phase. Regimens are available for adults, children, new and retreatment
cases.
FDC Formulation
Intensive phase 2 months RHZE (FDC4): RIF 150 mg + INH 75 mg + pyrazinamide 400 mg +
ethambutol 275 mg
Continuation phase 4 months RH (FDC2): RIF 150 mg + INH 75 mg 6.2.2
No. of daily tablets/grams according to body weight (kg)
Treatment regimen drug sensitive ,newly diagnosed
Intensive phase (RHZE tablet) depends on body weight: <35kg 2 tabs 35-50 3tabs
>50 4 tabs 2 months
Continuation phase (RH tablet) : : <35kg 2 tabs 35-50 3tabs >50 4 tabs for 4 months
*Change the number of tablets/grams if the weight change overtime.
** for patients over 70 kg bodyweight, additional 400 mg Pyrazinamide may be added by
the clinician in the intensive phase.
>>>>>>>>>>>>>>>>>>> Check smear at 8 weeks
Negative>>>>>>>>>>>>>. Start continuation phase
Positive >>>>>>>>>>>>>> Extend the intensive phase for another four weeks, then start the
continuation phase regardless of sputum test results.
Previously treated cases without drug resistant (Relapse, treatment after failure, treatment after loss
to follow up and other previously treated cases)
Retreatment Xpert/MTB/RIF result: MTB positive/ rifampicin resistant (RR) NOT detected
Central nervous system TB 9–12 months (2 months of intensive phase)
Osteo-articular TB 12 months (2 months of intensive phase)
Extensive pulmonary TB
Extend treatment to 12 months depending on clinical improvement (2 months of Intensive Phase)
